ArticleInternal medicine (Tokyo, Japan)2026
Alterations of the Cytokines, Chemokines, and Growth Factors in the Cerebrospinal Fluid of Patients with Advanced-stage Amyotrophic Lateral Sclerosis.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that mainly affects the motor neuron system and activates multiple molecular pathways including neuroinflammation. Changes in the levels of cytokines, chemokines, and growth factors in patients with advanced-stage ALS have not yet been reported. This study analyzed the levels of inflammatory cytokines, chemokines, and growth factors in the cerebrospinal fluid of ALS patients with an average ALS functional rating scale score revised (ALSFRS-R) of less than 10. Methods We analyzed the levels of 16 cytokines, 6 chemokines, and 5 growth factors in the CSF of patients with ALS. These levels were compared between patients with ALS and healthy controls. The relationship between ALSFRS-R and interleukin (IL)-1β, IL-2, and IL-15 levels was assessed. The discriminating ability of IL-1β, IL-2, and IL-15 was evaluated using a receiver operating characteristic curve analysis. Results The IL-1β, IL-2, and IL-15 levels in the CSF of patients with ALS were significantly higher than those in controls. IL-1β, IL-2, and IL-15 levels were negatively correlated with ALSFRS-R and demonstrated discriminatory ability between the ALS and control groups. Conclusion Our findings suggest that neuroinflammation may contribute to the pathomechanism of ALS, even in advanced stages, and that IL-1β, IL-2, and IL-15 may serve as potential immune parameters for advanced-stage ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.